HC Wainwright Reiterates “Buy” Rating for Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 46.65% from the stock’s previous close.

IRD has been the topic of a number of other reports. Citizens Jmp reissued a “market outperform” rating and set a $11.00 price target on shares of Opus Genetics in a report on Monday, June 15th. Chardan Capital reiterated a “buy” rating and set a $13.00 price objective on shares of Opus Genetics in a research note on Wednesday. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research report on Friday, July 17th. Finally, Zacks Research raised Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.69.

Opus Genetics Price Performance

IRD traded up $1.11 on Wednesday, reaching $5.46. 43,688,187 shares of the stock were exchanged, compared to its average volume of 1,229,557. Opus Genetics has a fifty-two week low of $1.32 and a fifty-two week high of $7.07. The firm has a market capitalization of $450.86 million, a PE ratio of -4.05 and a beta of 0.58. The company’s 50-day moving average price is $3.79 and its 200 day moving average price is $4.29.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. As a group, equities analysts forecast that Opus Genetics will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Opus Genetics

In related news, CFO Robert E. Gagnon sold 28,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at approximately $2,525,942.50. This trade represents a 4.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of the company’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the transaction, the chief executive officer directly owned 1,731,869 shares in the company, valued at $5,109,013.55. The trade was a 0.54% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 57,331 shares of company stock valued at $213,749. 11.70% of the stock is owned by insiders.

Institutional Trading of Opus Genetics

Several institutional investors have recently added to or reduced their stakes in IRD. Engineers Gate Manager LP purchased a new stake in shares of Opus Genetics in the 2nd quarter valued at $50,000. Occudo Quantitative Strategies LP acquired a new position in shares of Opus Genetics during the fourth quarter worth about $25,000. Stoneridge Investment Partners LLC acquired a new position in shares of Opus Genetics during the second quarter worth about $47,000. State of Wyoming purchased a new stake in shares of Opus Genetics during the second quarter worth approximately $65,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Opus Genetics during the second quarter worth approximately $66,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Promising Phase 1/2 data: All five patients in the low-dose Cohort 1 showed clinically meaningful improvements in visual function, with three experiencing improved best-corrected visual acuity and three of four evaluable patients showing improved retinal sensitivity. Four patients also demonstrated structural retinal improvements. No serious adverse events or dose-limiting toxicities were reported. Opus Genetics OPGx-BEST1 clinical trial announcement
• Positive Sentiment: Potential path to pivotal testing: Following an FDA Type C meeting, regulators aligned with a potential pivotal endpoint combining at least a three-decibel microperimetry improvement with patient-reported outcomes. Opus expects to complete Cohort 2 dosing in the fourth quarter of 2026, report initial data in the second quarter of 2027 and potentially begin Phase 3 dosing in 2027. The company expects its cash runway to extend into 2029. RTTNews OPGx-BEST1 report
• Positive Sentiment: Analyst support: BTIG Research reaffirmed a Buy rating with a $12 price target, while Chardan Capital maintained its Buy rating and $13 target. These targets imply substantial upside if the clinical program advances successfully.
• Positive Sentiment: Speculative positioning increased: Investors traded 4,820 call options, approximately 681% above typical volume, signaling heightened bullish interest and contributing to unusually heavy activity in the shares.
• Neutral Sentiment: Insider transaction: CFO Robert Gagnon sold 28,000 shares for approximately $127,120 to cover tax withholding tied to vested equity awards. Because the sale was tax-related and he retained more than 556,000 shares, the signal is limited.
• Negative Sentiment: Clinical-stage risk remains: The positive results come from only five low-dose participants, and a Phase 3 trial is still prospective. Larger studies could produce different efficacy or safety outcomes, leaving Opus Genetics dependent on further clinical milestones.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.